

31 March 2009

Proposal relating to the terms of listing of terazosin 1 mg (Apo-Terazosin)

PHARMAC is seeking feedback on a proposal to list Apotex's brand of terazosin hydrochloride 1 mg tablet (Apo-Terazosin) in the Pharmaceutical Schedule.

This proposal would mean that Apotex would supply the whole range of terazosin tablets (1 mg, 2 mg and 5 mg tablets - we have recently notified the acceptance of Apotex to be the sole supplier of terazosin 2 mg and 5 mg tablets from 1 October 2009).

Details of the proposal

Apotex's brand of terazosin hydrochloride 1 mg tablet (Apo-Terazosin) would be listed in Section B of the Pharmaceutical Schedule from 1 May 2009 as follows:

Chemical	Presentation	Brand	Pack size	Proposed price and subsidy
Terazosin hydrochloride	Tab 1 mg	Apo-Terazosin	28	\$2.50

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback please submit it in writing by 4 pm on **Wednesday, 8 April 2009** to:

Stephen Woodruffe	Email:
Therapeutic Group Manager	stephen.woodruffe@pharmac.govt.nz
PHARMAC	
PO Box 10 254	Fax: 04 916 7555
Wellington 6143	

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Background

Terazosin hydrochloride is used in the treatment of benign prostatic hyperplasia and hypertension. The 1 mg tablet is used as the starting dose (in order to minimise the risk of severe hypotensive effects) and in dose titration.